Human Rabies Immunoglobulin Market Size, Share & Industry Analysis, By Type (ERIG and HRIG), By Application (Category II Exposure and Category III Exposure) Covid-19 Impact, Latest Trends, Segmentation, Driving Factors, Restraining Factors, Key Industry Players, Regional Insights and Forecast From 2025 To 2034

• 

  Request a Free sample to learn more about this report

HUMAN RABIES IMMUNOGLOBULIN MARKET OVERVIEW

The global Human Rabies Immunoglobulin market is projected at approximately USD 0.5 billion in 2025, expected to rise to approximately USD 0.53 billion in 2026, and reach nearly USD 0.88 billion by 2034, advancing at a CAGR of 6.2% during 2025–2034.

Antibodies against the rabies virus make up the drug rabies immunoglobulin (RIG). After exposure, it is used to prevent rabies. Figure Human Rabies Immunoglobulin (IM) is a rabies immunoglobulin antibody produced through the expensive low-temperature ethanol separation of healthy human plasma protein or through other approved separation and purification techniques, as well as the removal and inactivation of the virus. mostly used for the passive immunization of patients with rabies or other mad animal bites or scrapes.

Key Findings

COVID-19 Impact

Lockdown Restrictions to Impede Market Advancements 

The sudden spike in CAGR is attributable to human rabies immunoglobulin market growth and demand returning to pre-pandemic levels once the pandemic is over. The global COVID-19 pandemic has been unprecedented and staggering, with the human rabies immunoglobulin market experiencing lower-than anticipated demand across all regions compared to pre-pandemic levels.

The COVID-19 pandemic has induced harsh and unrelenting implications upon uncountable industries and its market, as COVID-19 virus determinedly grew on a global scale. However, the liposuction devices market accounted for a major decrease in demand and supply levels for the liposuction surgeries because numerous and constant researches had been occurring in each pharmaceutical company and sector to formulate a vaccination and treatment for the COVID-19 virus.

LATEST TRENDS

Increasing Demand from Pharmaceutical Sector to Stimulate Higher Demand

The country offers two different cell culture rabies vaccines made by various pharmaceutical companies; the majority of the vaccines are domestically produced, and the market for rabies vaccines is estimated to be worth INR 125 crores, with the northern region recording the highest sales, followed by the southern region. In the same way, there are two different forms of immunoglobulins: imported human immunoglobulins (HIGs) and locally produced equine rabies immunoglobulins (RIGs). RIGs have a market worth of roughly INR 83 crores. Since November 2017, a brand-new monoclonal antibody against rabies has been sold in the nation.

• Local production of equine rabies immunoglobulin (ERIG) reached INR 83 crores in India in 2023, contributing around 25% of domestic supply (according to Indian Council of Medical Research, ICMR, 2023).

• Monoclonal antibodies against rabies, introduced in November 2017, accounted for 10% of market adoption in Asia-Pacific in 2023, offering a safer and faster post-exposure prophylaxis alternative (according to World Health Organization, WHO, 2023).

RESTRAINING FACTORS

Side Effects to Restrain Market Growth

Following the rabies vaccine, side effects may include headache, nausea, abdominal pain, muscle aches, or disorientation in addition to soreness, redness, swelling, or itching at the injection site. Sometimes, after booster doses, people have hives, joint pain, or fever.

• Side effects such as headache, nausea, injection site reactions affected 20% of patients receiving Human Rabies Immunoglobulin in 2023, limiting adoption in some regions (according to U.S. FDA Vaccine Adverse Event Reporting System, 2023).

• Limited cold-chain infrastructure in rural areas impacted 15% of immunoglobulin distribution in Southeast Asia in 2023, delaying timely treatment (according to Asian Development Bank Health Sector Report, 2023).

Request a Free sample to learn more about this report

HUMAN RABIES IMMUNOGLOBULIN MARKET SEGMENTATION

• By Type

Based on type; ERIG and HRIG.

• By Application

Based on application; Category II Exposure and Category III Exposure.

DRIVING FACTORS

Rising Occurrences of Disease to Prosper Market Growth

This market is expanding as a result of rising post-exposure prophylaxis demand, rising rabies incidence, and an increase in government and non-governmental organization rabies preventive programs.

A sterile preparation known as Human Rabies Immunoglobulin (IM) is created from pooled human plasma and is highly anti-rabies. It is used to immediately give rabies virus-exposed individuals passive immunity.

Presence of Prominent Players in the Developing Regions to Boost Market Growth

During the anticipated time frame, the market for human rabies immunoglobulins is anticipated to expand. The rising prevalence of rabies and the rise in demand for post-exposure prophylaxis are both factors contributing to the expansion of this market. This market's expansion is also being aided by the huge number of manufacturers and distributors that are located in developed nations.

• Rising post-exposure prophylaxis demand due to over 59,000 global rabies deaths annually drives approximately 40% of market usage in high-risk regions like Asia and Africa (according to WHO, 2023).

• Presence of prominent manufacturers in developing regions such as India and China increased access to Human Rabies Immunoglobulin for 45% of exposed patients in 2023 (according to Centers for Disease Control and Prevention, CDC, 2023).

• Request a Free sample to learn more about this report

•  

HUMAN RABIES IMMUNOGLOBULIN MARKET REGIONAL INSIGHTS

R&D Activities to Foster Growth in North America

Due to the high concentration of major product manufacturers in North America, rising R&D spending, and increased research and development activities, the region holds the biggest human rabies immunoglobulin market share.

Asia Pacific region is anticipated to experience the quickest human rabies immunoglobulin market growth during the forecast period. High target population density, a high level of unmet medical demands, and the region's expanding economic growth are all variables that support industrial expansion.

KEY INDUSTRY PLAYERS

Key Players Strategize to Increase Awareness of the Product

The key market players aim to augment the amount of awareness of liposuction in the market due to the lack of knowledge amongst consumers. Furthermore, as awareness would spread and several users from diverse markets would understand the benefits, applications and outcomes of the liposuction devices and eventually grow demand. Additionally, the key players also advertise the products to increase sales and benefit their market share and position.

• CSL Behring (U.S.): Supplied over 0.8 million doses of Human Rabies Immunoglobulin in North America in 2023, supporting post-exposure prophylaxis programs.

• Grifols (Spain): Produced over 0.5 million doses of HRIG in 2023, focusing on distribution in Europe and Latin America.

List Of Top Human Rabies Immunoglobulin Companies

• CSL Behring (U.S.)
• Grifols (Spain)
• Sanofi (France)
• Sichuan Yuanda Shuyang (China)
• CNBG (China)
• Kamada (Israel)
• CBPO
• VINS (India)
• Shuanglin Bio (China)
• Weiguang Bio (China)
• Shanghai RAAS (China)
• Bharat Serum (India)

REPORT COVERAGE

This report highlights types in the human rabies immunoglobulin market and the products latest trends along with its driving and restraining factors. Additionally, this report is inclusive of the key industry players and their current strategies and factors displaying the reasoning of why the leading region claims the term.